LEERINK PARTNERS

Why Yorvipath® is a Good Deal for Society



Published on: February 04, 2025

> GCEA shows Yorvipath’s long-term societal benefits for chronic hypoparathyroidism can outweigh its cost even at US market-based pricing over the exclusivity period.

Based on our societal impact analysis, **we anticipate that Yorvipath will have a positive or neutral impact on all 24 value elements**. Adults living with hypoparathyroidism now have a treatment option. The U.S. Food and Drug Administration approved Yorvipath (palopegteriparatide; developed as TransCon PTH by Ascendis Pharma) in August 2024.

For individuals living with chronic hypoparathyroidism, Yorvipath is expected to improve quality of life, reduce long-term kidney complications, extend life, reduce uncertainty in health outcomes, and increase labor and non-labor productivity. For caregivers, Yorvipath is expected to result in substantially less time caregiving with positive impacts on a caregiver's quality of life. For the healthcare system, Yorvipath is expected to lower costs associated with inadequately controlled hypoparathyroidism and long-term complications such as kidney disease. And for society, we have a treatment for hypoparathyroidism that may result in scientific spillovers and future generic equivalents offering value to society long after its branded period.

Our generalized cost-effectiveness analysis suggests the long-term **societal benefits of Yorvipath can outweigh its cost** (even at US market-based pricing over the exclusivity period).

Read our full report for a description of our assumptions, inputs, and findings that describe why the US market-based price for Yorvipath makes sense when considering its long-term societal benefits and future price changes.

The Leerink Center for Pharmacoeconomics is a division of MEDACorp and an affiliate of Leerink Partners

Leerink Center for Pharmacoeconomics

- Melanie Whittington, PhD, Managing Director, Head of the Center for Pharmacoeconomics

Contributors:

Melanie Whittington

Center for Pharmacoeconomics

Disclosures:

This information (including, but not limited to, prices, quotes, and statistics) has been obtained from sources that we believe reliable, but we do not represent that it is accurate or complete and it should not be relied upon as such. All information is subject to change without notice, and the information and any opinions contained herein are as of the date of this material and the Firm does not undertake any obligation to update them. The information is not an offer to sell or a solicitation to buy any product to which this information relates. Leerink Partners LLC ("Firm"), its officers, directors, employees, proprietary accounts, and affiliates may have a position, long or short, in the securities referred to in this report, and/or other related securities, and from time to time may increase or decrease the position or express a view that is contrary to that contained in this piece. The Firm's research analysts, bankers, salespeople, and traders may provide oral or written market commentary or trading strategies that are contrary to opinions expressed, and the Firm's market making desk may make investment decisions that are inconsistent with the opinions expressed in this document. The past performance of securities does not guarantee or predict future performance. This material does not take into account individual circumstances, objectives, or needs and is not intended as a recommendation to any particular person(s). As such, the financial instruments discussed herein may not be suitable for all investors, and investors must make their own investment decisions based upon their specific investment objectives and financial situation. This material is a marketing communication and is not and should not be construed as investment research or a research report prepared by a research analyst. Any views portrayed in this material may differ from those of the research department of Leerink Partners LLC. All information contained herein is intended solely for your own personal, informational use, and you are not permitted to reproduce, retransmit, disseminate, sell, license, distribute, republish, broadcast, post, circulate or commercially exploit the information in any manner or media without the express written consent of Leerink Partners LLC, or to use the information for any unlawful purpose. Additional information is available upon request by contacting the Editorial Department, Leerink Partners LLC, 53 State Street, 40th Floor, Boston, MA 02109.MEDACorp LLC (MEDACorp), an affiliate of Leerink Partners LLC, is a global network of independent healthcare professionals (Key Opinion Leaders and consultants) providing industry and market insights to Leerink Partners and its clients.
Member FINRA/SIPC